List view / Grid view

Hereditary Angioedema (HAE)

Filter the results



Shire to acquire Dyax; expands HAE pipeline

3 November 2015 | By Victoria White

Shire has announced that it is to acquire Dyax, a company focused on the development of plasma kallikrein inhibitors for the treatment of hereditary angioedema, for approximately $5.9 billion...